Bausch Health Companies | VRX - Cash And Equivalent



Bausch Health Companies reported $1.73B in Cash and Equivalent for its fiscal quarter ending in June of 2025.


Cash And Equivalent Change Date
Amgen USD 8.03B 782M Jun/2025
ANI Pharmaceuticals USD 217.8M 67.99M Jun/2025
Aurora Cannabis CAD 140.16M 31.45M Jun/2025
Bausch Health Companies USD 1.73B 593M Jun/2025
Biogen USD 2.76B 160.5M Jun/2025
Bristol-Myers Squibb USD 12.6B 1.72B Jun/2025
Canopy Growth CAD 126.2M 109.89M Jun/2025
Corcept Therapeutics USD 102.74M 12.93M Jun/2025
Danaher USD 2.96B 964M Jun/2025
Drreddys Laboratories INR 9B 7.91B Jun/2025
Eli Lilly USD 3.38B 282.6M Jun/2025
Gilead Sciences USD 5.14B 2.78B Jun/2025
Novo Nordisk A/S 18.44B 5.78B Jun/2025
Pacira USD 300.48M 16.87M Jun/2025
Perrigo USD 454.2M 44.3M Jun/2025
Prestige Brands USD 139.5M 41.62M Jun/2025
Supernus Pharmaceuticals USD 144.71M 28.86M Jun/2025
Vertex Pharmaceuticals USD 6.38B 1.71B Jun/2025
Zoetis USD 1.44B 286M Jun/2025